Gilead Agrees to Acquire Arcellx in $7.8 Billion Deal to Bolster Cancer Pipeline

Gilead Sciences has entered into a definitive agreement to acquire Arcellx, Inc. (ACLX) in a cash-and-stock transaction with a maximum value of $7.8 billion. The deal, structured as a merger, includes an upfront payment of $5.5 billion, with additional contingent consideration of up to $2.3 billion tied to the successful development and commercialization of Arcellx’s lead asset, axi-cel, an investigational CAR T-cell therapy targeting B-cell malignancies. The acquisition underscores Gilead’s strategic pivot toward advanced oncology therapies, particularly in the rapidly evolving field of autologous cell and gene treatments. Arcellx’s proprietary platform and clinical-stage pipeline, including axi-cel and a next-generation candidate targeting solid tumors, are expected to significantly enhance Gilead’s immunotherapy portfolio. The integration of Arcellx’s research and development capabilities is anticipated to accelerate the timeline for bringing new treatments to market. Shares of ACLX surged over 40% in pre-market trading following the announcement, reflecting strong investor confidence in the deal’s potential. Gilead’s stock (GILD) saw a modest dip, consistent with market pricing for large-scale acquisitions. The transaction is expected to close by the third quarter of 2026, subject to regulatory approvals and customary closing conditions. The deal also places Gilead in a stronger position within the broader Nasdaq-100 (^NDX) index, which includes several major biotech firms. The acquisition is likely to influence investor sentiment across the biotechnology sector, particularly for companies with late-stage clinical programs in immuno-oncology. With the deal’s scale and focus on next-generation therapies, it may encourage further consolidation in the space as firms seek to strengthen their innovation pipelines.